Anticoagulation in deep vein thrombosis — Frequently asked questions (FAQ)
1) What is the purpose of anticoagulation in deep vein thrombosis?
The main aims of anticoagulation are to prevent thrombus progression, reduce the risk of pulmonary embolism, prevent recurrent thromboembolic events and decrease the likelihood of developing post-thrombotic syndrome.
2) Do all patients with DVT require anticoagulation?
Most patients with deep vein thrombosis require anticoagulation. However, the decision should take into account bleeding risk, thrombus location, comorbidities, renal function and any contraindications to treatment.
3) When should apixaban or rivaroxaban be preferred?
Apixaban and rivaroxaban may be started immediately after diagnosis without prior treatment with low-molecular-weight heparin. They are often selected because of their ease of use and proven efficacy in the treatment of DVT.
4) When should dabigatran be used?
Dabigatran requires at least 5 days of prior anticoagulation with low-molecular-weight heparin before it is started. It should be used cautiously in older patients or those with impaired renal function and is contraindicated in severe renal impairment.
5) In which situations does warfarin remain a relevant option?
Warfarin continues to play an important role in patients with severe renal impairment, mechanical heart valves, high-risk antiphospholipid syndrome or contraindications to direct oral anticoagulants. It requires regular INR monitoring.
6) What is the usual duration of anticoagulation?
The duration depends on the clinical context. In general, a minimum of 3 months is recommended. After this period, the balance between the risk of thrombotic recurrence and bleeding should be reassessed to determine whether treatment should be extended.
7) How should DVT associated with active malignancy be managed?
Anticoagulation should usually be continued while the malignancy remains active or cancer treatment is ongoing. Apixaban and low-molecular-weight heparin are commonly used options in this setting.
8) When should thrombophilia testing be considered?
Testing may be considered in selected situations, such as thrombosis at a young age, recurrent episodes, a significant family history or thrombosis at an unusual site. It is not routinely indicated in all patients with DVT.
9) Are there situations in which DOACs should be avoided?
Direct oral anticoagulants should generally be avoided in patients with mechanical heart valves, moderate or severe mitral stenosis, high-risk antiphospholipid syndrome, severe renal impairment, pregnancy or advanced liver disease.
10) Which anticoagulant has the lowest bleeding risk?
Among direct oral anticoagulants, apixaban has consistently shown a favourable safety profile, with a lower risk of major bleeding in several comparative studies.
11) What should be done if a new DVT occurs during anticoagulation?
Recurrence should be confirmed, and treatment adherence, drug interactions, dosing and possible progression of malignancy should be assessed. It may be necessary to change the anticoagulation strategy or refer the patient for specialist assessment.
